Document is current
Any future updates will be listed below
-
Authors
Martin, Sebastian
Viertl, David
Janz, Anna
Habringer, Stefan
Keller, Ulrich
Schottelius, Margret http://orcid.org/0000-0002-1928-6913
-
Funding
Funding for this research was provided by:
PentixaPharm GmbH (Service contract)
University of Lausanne
- License Information
-
More Information
Article History
Received: 20 March 2023
Accepted: 2 May 2023
First Online: 10 May 2023
Declarations
:
: All in vivo experiments were conducted in compliance with the ARRIVE guidelines and according to the Swiss Federal Veterinary Office guidelines and were approved by the Cantonal Veterinary Office (permit number VD3595).
: Not applicable.
: Not applicable.
: PentixaPharm GmbH is the exclusive IP license holder for PentixaFor and PentixaTher (WO/2020/053256A1, EP/2019/074196W; WO/2015/185162A1, EP2014/061875; WO/2011/131735, EP2011/056358). M.S. is listed as a coinventor on the respective patents. M.S. and U.K. are scientific advisors for PentixaPharm GmbH. Anna Janz is an employee of PentixaPharm GmbH.
